Stock Price, News, Quote and Profile of Kalytera Therapeutics Inc(TSX-V:KLY) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

Kalytera Therapeutics Inc

TSX-V:KLY (4/9/2021, 2:54:46 PM)

0.045

0 (0%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorN/A

GICS IndustryN/A

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap25.70M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

Canadian Stock Screener

Find more stocks on the Canadian

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the Canadian

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the Canadian

Company Profile

Company Info

Kalytera Therapeutics Inc

4040 Civic Center Drive

San Rafael CA 94903

P: +1 415 218-3900

CEO: Robert E. Farrell

KLY.CA News

2 years ago - Claritas Pharmaceuticals, Inc.Claritas Secures $5 Million Equity Financing Facility with Alumina Partners (Ontario) Ltd.

SAN FRANCISCO, CA and TORONTO, ON, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or...

2 years ago - Claritas Pharmaceuticals, Inc.Claritas to Develop R-107 for Treatment of PPHN, a Potentially Fatal Pulmonary Disorder in Newborns

SAN FRANCISCO, CA, and TORONTO, ON, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or...

2 years ago - Claritas Pharmaceuticals, Inc.Claritas Completes Acquisition of Exclusive Worldwide Rights to Develop and Commercialize R-107 for Pulmonary Disease

Data in Animal Model of PAH Demonstrate Ability of R-107 to Reverse Progression of the Disease...

2 years ago - Claritas Pharmaceuticals, Inc.Claritas Announces Publication of Peer-Reviewed Article Reporting that R-107 Significantly Improved Multi-Organ Function and Survival in an Ovine (Sheep) Model of Sepsis

Claritas to Initiate Phase 2 Clinical Testing of R-107 in Treatment of COVID-Related Sepsis Following Completion of Phase 1 Study...

2 years ago - Claritas Pharmaceuticals, Inc.Claritas Provides Update Regarding Phase 1 Clinical Study

SAN FRANCISCO and TORONTO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or...

3 years ago - Claritas Pharmaceuticals, Inc.Claritas Announces Engagement of B. Riley Securities as Sponsor for the Company’s Planned Up-Listing of its Securities to the OTCQB

SAN FRANCISCO and TORONTO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: CLAS.V) (the "Company" or...

Kalytera Therapeutics Inc (KLY.CA)